All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression

May 28th 2024

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.

Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma

May 28th 2024

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.

Broadening Differentials in Brain-Metastatic Prostate Cancer Expand Diagnostic Horizons

May 28th 2024

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.

Fox Chase Cancer Center’s Dr. Sameer Patel Named Vice President of the Robert H. Ivy Society of Plastic Surgeons

May 28th 2024

Sameer Patel, MD, FACS, of Fox Chase Cancer Center, was recently named Vice President of the Robert H. Ivy Society of Plastic Surgeons.

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in High-Risk Early TNBC

May 28th 2024

Perioperative pembrolizumab plus chemotherapy improved survival vs preoperative chemotherapy in high-risk, early-stage, triple-negative breast cancer.

Dato-DXd Provides Numerical, But Not Significant, OS Benefit in Pretreated Advanced NSCLC

May 28th 2024

Dato-DXd elicited a clinically meaningful but not statistically significant improvement in overall survival in pretreated, advanced non–small cell lung cancer.

FDA Approval Sought for Use of TLX007-CDx in PSMA PET Imaging of Prostate Cancer

May 28th 2024

The FDA has received a new drug application for the use of TLX007-CDx in the preparation of PSMA PET imaging of prostate cancer.

Data for Quadruplet Therapies Could Alter Frontline SOC for Transplant-Ineligible Multiple Myeloma

May 28th 2024

Muhamed Baljevic, MD, FACP, discusses the investigation of frontline quadruplet therapies in transplant-ineligible multiple myeloma.

Overcoming Adversity and Achieving the American Dream in Cancer Care

May 28th 2024

From barely escaping a life under communism in a Russia-occupied Latvia to overcoming a family health crisis, Robert F. Ozols, MD, PhD, knows a thing or two about beating the odds.

Whole Genome Sequencing for AML/MDS Risk Stratification

May 27th 2024

Two clinical trials for AML or MDS are open and enrolling at Siteman Cancer Center and Washington University School of Medicine in St. Louis.

Retrospective Data Shed Light on Prognostic Value of PD-L1 Expression in Metastatic Papillary RCC

May 27th 2024

Positive PD-L1 expression was associated with worse survival in metastatic papillary renal cell carcinoma.

Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges

May 27th 2024

Janet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.

FDA Grants Priority Review to Isatuximab Combo for Newly Diagnosed, Transplant-Ineligible Myeloma

May 27th 2024

The FDA granted priority review to the sBLA for isatuximab plus bortezomib/lenalidomide/dexamethasone for newly diagnosed, transplant-ineligible myeloma.

CAR T-Cell Therapy Makes its Mark in CLL

May 26th 2024

David L. Porter, MD, discusses CAR T-cell therapy in chronic lymphocytic leukemia and looks towards improvements and unmet needs that remain.

First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma

May 25th 2024

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.

Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond

May 24th 2024

Sanjal Desai, MD, expands on the safety, efficacy, and sequencing of BTK inhibitors and venetoclax-based regimens in chronic lymphocytic leukemia.

Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

May 24th 2024

James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.

Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer

May 24th 2024

Ribociclib plus endocrine therapy bested combination chemotherapy in terms of progression-free survival in HR-positive, HER2-negative advanced breast cancer.

ARROS-1 Trial of Zidesamtinib Aims to Address Current TKI Limitations in ROS1+ NSCLC

May 24th 2024

Stephen V. Liu, MD, details the phase 1/2 ARROS-1 study evaluating the selective ROS1 inhibitor zidesamtinib in patients with ROS1 fusion–positive non–small cell lung cancer.

Prostate Cancer Study: More Health Benefits from Plant-Based Diet

May 24th 2024

Eating more fruits, nuts and vegetables each day – along with fewer animal products – is associated with a nearly 50% reduction in the risk of prostate cancer progression.